An Off-the-Shelf Cell Therapy to Calm Cytokine Storms

Small molecule drugs and monoclonal antibodies often fall short at addressing severe inflammatory and immune‑mediated diseases. Mesoblast has spent more than 15 years industrializing mesenchymal stromal cell therapies to treat these conditions. In late 2024, it won U.S. Food and Drug Administration approval for Ryoncil, the first mesenchymal stromal cell therapy approved in the United States. Ryoncil is approved to treat steroid‑refractory acute graft‑versus‑host disease in pediatric patients 2 months of age and older. Mesoblast founder and CEO Silviu Itescu discusses how this class of therapy can help dampen cytokine‑driven hyperinflammation, how the company is extending its platform into other high‑burden conditions, and what distinguishes its second‑generation cell therapy now in development from its first.

You can listen to An Off-the-Shelf Cell Therapy to Calm Cytokine Storms online on Radio and Podcast. Open the player on this page to stream the available audio.

An Off-the-Shelf Cell Therapy to Calm Cytokine Storms is an episode from The Bio Report by Levine Media Group.

This episode is 28:29 long.

This episode was published on Apr 29, 2026.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from The Bio Report when more episodes are available from the podcast feed.